Gastroesophageal Adenocarcinoma Clinical Trials
5 recruiting trials for Gastroesophageal Adenocarcinoma. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Gastroesophageal Adenocarcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 40% (2 studies); the largest phase groups are Phase 2: 2, Phase 1 / Phase 2: 2, Phase 1: 1.
Research is led by Yale University (1), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1), Bolt Biotherapeutics, Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Sequential cytoreductive intervention (procedure, 1 trial), followed by Signatera Genome ultra-sensitive ctDNA blood test, Zanidatamab.
Track Gastroesophageal Adenocarcinoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With...
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with...
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal...
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with...
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric...
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus...
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Gastroesophageal Adenocarcinoma, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Gastroesophageal Adenocarcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Gastroesophageal Adenocarcinoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.